Platinum Investment Management Ltd. purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 19,138 shares of the biopharmaceutical company’s stock, valued at approximately $1,598,000. Several other hedge funds have also made changes to their positions in the company. Seven Eight Capital LP purchased […]
Sectoral Asset Management Inc. reduced its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 94.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 7,013 shares of the biopharmaceutical company’s stock after selling 111,290 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Cytokinetics were worth $586,000 as of its most […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) Director Robert Arthur Harrington sold 1,580 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $48.64, for a total transaction of $76,851.20. Following the sale, the director now directly owns 15,541 shares in the company, valued […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) Director Robert Arthur Harrington sold 1,580 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $48.64, for a total value of $76,851.20. Following the transaction, the director now directly owns 15,541 shares in the company, valued […]